CN116603098A - Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof - Google Patents
Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof Download PDFInfo
- Publication number
- CN116603098A CN116603098A CN202310765188.8A CN202310765188A CN116603098A CN 116603098 A CN116603098 A CN 116603098A CN 202310765188 A CN202310765188 A CN 202310765188A CN 116603098 A CN116603098 A CN 116603098A
- Authority
- CN
- China
- Prior art keywords
- solution
- hydrogel
- mxene
- freeze
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 55
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 11
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims abstract description 40
- 206010052428 Wound Diseases 0.000 claims abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 34
- 229920001661 Chitosan Polymers 0.000 claims abstract description 29
- 229920001690 polydopamine Polymers 0.000 claims abstract description 23
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 22
- 229940074391 gallic acid Drugs 0.000 claims abstract description 20
- 235000004515 gallic acid Nutrition 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 17
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 17
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 17
- 230000001684 chronic effect Effects 0.000 claims abstract description 8
- 239000000463 material Substances 0.000 claims abstract description 6
- 230000008439 repair process Effects 0.000 claims abstract description 5
- 230000003647 oxidation Effects 0.000 claims abstract description 4
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 4
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 3
- 230000003993 interaction Effects 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 30
- 239000002244 precipitate Substances 0.000 claims description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 20
- 229910021641 deionized water Inorganic materials 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 18
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 claims description 15
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 15
- 229910052786 argon Inorganic materials 0.000 claims description 15
- 229960001149 dopamine hydrochloride Drugs 0.000 claims description 15
- 239000002135 nanosheet Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000000502 dialysis Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 5
- 241000872931 Myoporum sandwicense Species 0.000 claims description 5
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- PQXKHYXIUOZZFA-UHFFFAOYSA-M lithium fluoride Chemical compound [Li+].[F-] PQXKHYXIUOZZFA-UHFFFAOYSA-M 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000009210 therapy by ultrasound Methods 0.000 claims description 5
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000003064 anti-oxidating effect Effects 0.000 claims description 2
- 230000001788 irregular Effects 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- 230000037314 wound repair Effects 0.000 claims description 2
- 206010060803 Diabetic foot infection Diseases 0.000 claims 1
- 230000001133 acceleration Effects 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000001339 epidermal cell Anatomy 0.000 claims 1
- 238000011049 filling Methods 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000013049 sediment Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 12
- 230000001154 acute effect Effects 0.000 abstract description 2
- 238000004132 cross linking Methods 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000006392 deoxygenation reaction Methods 0.000 description 3
- 238000000527 sonication Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides an injectable conductive hydrogel with an antioxidant stress characteristic, and a preparation method and application thereof. The multi-functional hydrogel is prepared from multiple components such as gallic acid modified chitosan, oxidized hyaluronic acid, polydopamine coated MXene and the like through covalent crosslinking and supermolecular interaction, has excellent adhesiveness, injectability, conductivity, broad-spectrum antibacterial property and stronger oxidation resistance, is an ideal wound dressing, and can be used as an auxiliary material for rapid repair and tissue regeneration of acute/chronic wounds such as diabetes.
Description
Technical Field
The invention belongs to the technical field of high polymer materials, and particularly relates to a preparation method of novel injectable conductive hydrogel with broad-spectrum antibacterial and antioxidant stress characteristics and application of the novel injectable conductive hydrogel in the aspect of rapidly repairing diabetic wounds.
Background
Skin is the largest organ of the human body and is an important natural barrier against external hazards. Once the integrity of the skin is damaged, the original protection mechanism of the skin is damaged, and the life health of people is seriously affected. Meanwhile, chronic wounds are more susceptible to bacterial infection than ordinary wounds and are also more difficult to heal. Classical cases of chronic wounds are diabetic wounds, where up to 25% of diabetics may have a risk of non-healing of the chronic wound for life, mainly due to excessive oxidative stress and insufficient angiogenesis induced by hyperglycemia. Typically, the healing process includes four phases: hemostasis, inflammation, proliferation and remodeling stages. The most difficult to repair in diabetic wounds is the persistent inflammatory phase associated with the formation of granulation tissue and impaired maturation, where high oxidative stress predominates. Oxidative stress in type II diabetes is the result of increased metabolic byproducts and impaired ROS detoxification at high concentrations of circulating glucose. Therefore, a novel therapeutic strategy for diabetic wounds that is resistant to oxidative stress would be highly desirable.
Disclosure of Invention
The invention aims to provide a novel conductive hydrogel with injectable, broad-spectrum antibacterial and antioxidant stress characteristics and application thereof in the aspect of rapidly repairing diabetic wounds.
The method prepares a multifunctional conductive hydrogel (GHPM) by adding polydopamine coated MXene nano-sheets (MXene@PDA) into oxidized hyaluronic acid (HA-ALD) and grafting the polydopamine coated MXene nano-sheets with gallic acid grafted chitosan (CS-GA) through dynamic Schiff base chemical crosslinking and supermolecular action.
The hydrogels exhibit excellent tissue adhesion, injectability, electrical conductivity, rapid self-healing, good oxidation resistance, and broad-spectrum antimicrobial properties. Proved by cytotoxicity tests, animal tests and the like, the hydrogel can be used as a wound dressing for rapid repair of diabetic wounds. By combining the characteristics, the novel injectable, broad-spectrum antibacterial and antioxidant multifunctional hydrogel has great potential as a novel wound dressing for rapidly repairing chronic wounds such as diabetic wounds and the like, and can be widely used in biomedical fields such as tissue engineering and the like.
The invention relates to a preparation method of novel injectable conductive hydrogel with broad-spectrum antibacterial and antioxidant stress characteristics, which comprises the following specific steps:
(1) 1g of lithium fluoride (LiF) was dissolved in a dilute hydrochloric acid (HCl) solution and stirred thoroughly, after which Ti was dissolved 3 AlC 2 Slowly adding the powder into the above solution, reacting at 35deg.C in water bath for 24 hr, centrifuging at 5000rpm for 5min, washing the precipitate with water to pH of the supernatant liquid>6. The precipitate was collected and added to 100mLH 2 O, deoxidizing under argon for 15min, and then carrying out ultrasonic treatment for 1h. Finally, the precipitate is removed by centrifugation again, and the collected liquid is freeze-dried to obtain the etched MXene nano-sheet. And (3) introducing argon to protect the freeze-dried MXene nano-sheet powder for later use.
(2) 20mg of MXene was dissolved in water and subjected to ultrasonic dispersion, and Tris-HCl buffer (1M) was added to adjust the pH of the solution to about 8.5. To the above solution, a certain amount of dopamine hydrochloride (DA) was added, and reacted for 1 hour under an air atmosphere. The reaction solution was then centrifuged at 8900rpm for 10min, and the precipitate was washed with water 3 times to remove unreacted DA. Finally, the precipitate was collected by centrifugation and freeze-dried to give the final product mxene@pda. And (5) introducing argon into the freeze-dried MXene@PDA powder for storage for later use.
(3) 1.5g Chitosan (CS) was dissolved in deionized water with pH adjusted to about 5 with 5M HCl to form a 1wt% chitosan solution. Heating the solution to 50deg.C in a water bath, and using N 2 Deoxidizing for 15min, and then adding 0-1.5 g of Gallic Acid (GA) into the chitosan solution. 575.1mg of N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (EDC) and 345.3mg of N-hydroxysuccinimide (NHS) were dissolved in a mixture of 50mL of ethanol and water (1:1, v/v), and added dropwise to the above mixed solution, in N 2 The reaction was carried out for 10 hours under ambient conditions and the pH was kept at 5. The resulting solution was dialyzed in acidified deionized water containing NaCl for 3 days using a dialysis bag. Finally, the obtained solution was freeze-dried to obtain gallic acid-modified chitosan powder (CS-GA).
(4) 1g of Hyaluronic Acid (HA) was dissolved in 100mL of deionized water, and after stirring well, 1g of sodium periodate (NaIO) was added thereto 4 ) The reaction was carried out for 3h under dark conditions. Then, 3mL of ethylene glycol was added to the above solution to terminate the reaction, and stirring was continued for 1h. The resulting solution was dialyzed in deionized water using a dialysis bag for three days, and finally the resulting solution was freeze-dried to obtain the aldehyde-formed hyaluronic acid (HA-ALD).
(5) Water is used as solvent to prepare a solution containing 5wt% of HA-ALD and Mxene@PDA (0-5 mg/mL) and the solution is uniformly mixed by ultrasound. Then, the above solution was mixed with 3wt% CS-GA aqueous solution in a volume ratio of 1:1, shaking and mixing. The injectable hydrogel is obtained after uniform mixing.
In the method, the antibacterial polymer can be natural or synthetic polymer bacteriostat such as chitosan, gallic acid, polydopamine and the like.
The invention has the following advantages: 1. the multifunctional hydrogel has excellent adhesiveness, conductivity and injectability, has stronger adhesiveness for different organic and inorganic surfaces, can be used as wound dressing to fill deep wound surfaces with irregular shapes, and provides microenvironment for tissue growth and functions; 2. the hydrogel has broad-spectrum antibacterial property and oxidation resistance, can ensure that the material plays an antibacterial role for a long time, and has excellent capability of scavenging free radicals; 3. the scanning electron microscope image of the freeze-dried hydrogel shows that the hydrogel is of a loose porous structure, is convenient for absorbing wound seepage, and can be used for storing and releasing medicines and bioactive molecules; 4. the hydrogel has wide sources of raw materials, is easy to store, has good biocompatibility and is favorable for commercialization of products; 5. the hydrogel provided by the invention has the characteristics of antioxidation stress as a dressing, and has the function of rapidly repairing the diabetic wound surface; 6. the invention is suitable for dressing of acute/chronic wound surface under different environments, tissue regeneration auxiliary material and the like, and has wide application prospect.
Drawings
Fig. 1: phase transition diagram of the multifunctional hydrogel dressing prepared in example 1. By comparing the front-to-back changes of the substances in the inclined reagent bottles, we can see that the hydrogel precursor solution turns into black gel 15s after being uniformly mixed. Indicating that the hydrogels are injectable.
Fig. 2: scanning electron microscopy images of the multifunctional hydrogel dressing prepared in example 1 after lyophilization. From the figure, we can clearly see the loose and porous structure inside the hydrogel, which is beneficial to carrying and releasing the medicine and exchanging the substances.
Fig. 3: the multifunctional hydrogel dressing prepared in the embodiment 1 is adhered to the attached drawings of different materials. It can be seen that the prepared hydrogel can be adhered to the surfaces of different substances, and has stronger adhesion.
Fig. 4: an in vitro antibacterial experimental graph of the multifunctional hydrogel dressing prepared in the embodiment 1. The hydrogel of the invention has excellent broad-spectrum antibacterial performance. The GHPM hydrogel group had a minimum colony count and almost 100% inhibition of E.coli and Staphylococcus aureus, indicating that the synergistic antibacterial effect of CS-GA, MXene and PDA resulted in bacterial cell membrane damage and leakage of cytoplasmic contents. The corresponding hydrogel GH without Mxene@PDA has moderate bacterial colony numbers in the antibacterial experiment, and shows that the hydrogel GH has a general antibacterial effect. The other corresponding hydrogel which contains neither gallic acid GA nor Mxene@PDA, namely hydrogel CH for short, has the largest colony number in the antibacterial experiment and relatively worst antibacterial effect.
Fig. 5: the multifunctional hydrogel dressing prepared for the embodiment 1 is used for repairing diabetic foot wound patterns of mice. From the figure, it can be seen that the control mice had no significant improvement in wound healing after 18 days of wound repair, and did not heal completely; the hydrogel group mice wound is completely healed, which shows that the hydrogel can be used as wound dressing to quickly and effectively repair diabetic foot wound surface.
Detailed Description
Example 1:
(1) 1g of lithium fluoride (LiF) was dissolved in a dilute hydrochloric acid (HCl) solution and stirred thoroughly, after which Ti was dissolved 3 AlC 2 Slowly adding the powder into the above solution, reacting at 35deg.C in water bath for 24 hr, centrifuging at 5000rpm for 5min, washing the precipitate with water to pH of the supernatant liquid>6. The precipitate was collected and added to 100mLH 2 O, deoxidizing under argon for 15min, and then carrying out ultrasonic treatment for 1h. Finally, the precipitate is removed by centrifugation again, and the collected liquid is freeze-dried to obtain the etched MXene nano-sheet. And (3) introducing argon to protect the freeze-dried MXene nano-sheet powder for later use.
(2) 20mg of MXene was dissolved in water and subjected to ultrasonic dispersion, and Tris-HCl buffer (1M) was added to adjust the pH of the solution to about 8.5. To the above solution, a certain amount of dopamine hydrochloride (DA) was added, and reacted for 1 hour under an air atmosphere. The reaction solution was then centrifuged at 8900rpm for 10min, and the precipitate was washed with water 3 times to remove unreacted DA. Finally, the precipitate was collected by centrifugation and freeze-dried to give the final product mxene@pda. And (5) introducing argon into the freeze-dried MXene@PDA powder for storage for later use.
(3) 1.5g Chitosan (CS) was dissolved in deionized water with pH adjusted to about 5 with 5M HCl to form a 1wt% chitosan solution. Heating the solution to 50deg.C in a water bath, and using N 2 Deoxygenation is performed for 15min, and then 1.5g of Gallic Acid (GA) is added to the chitosan solution. 575.1mg of N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (EDC) and 345.3mg of N-hydroxysuccinimide (NHS) were dissolved in a mixture of 50mL of ethanol and water (1:1, v/v), and added dropwise to the above mixed solution, in N 2 The reaction was carried out for 10 hours under ambient conditions and the pH was kept at 5. The resulting solution was dialyzed in acidified deionized water containing NaCl for 3 days using a dialysis bag. Finally, the obtained solution was freeze-dried to obtain gallic acid-modified chitosan powder (CS-GA).
(4) 1g of Hyaluronic Acid (HA) was dissolved in 100mL of deionized water, and after stirring well, 1g of sodium periodate (NaIO) was added thereto 4 ) The reaction was carried out for 3h under dark conditions. Then, 3mL of ethylene glycol was added to the above solution to terminate the reaction, and stirring was continued for 1h. The resulting solution was dialyzed in deionized water using a dialysis bag for three days, and finally the resulting solution was freeze-dried to obtain the aldehyde-formed hyaluronic acid (HA-ALD).
(5) A solution containing 5wt% of HA-ALD and Mxene@PDA (5 mg/mL) was prepared with water as a solvent and mixed well by sonication. Then, the above solution was mixed with 3wt% CS-GA aqueous solution in a volume ratio of 1:1, shaking and mixing. The injectable hydrogel is obtained after uniform mixing. The bacterial colony number in the antibacterial experiment of the GHPM hydrogel is almost zero, which shows that the inhibition rate of the GHPM hydrogel to escherichia coli and staphylococcus aureus is almost 100%. The composition has excellent antibacterial effect, and the result of repairing the diabetic wound surface is obtained most rapidly.
Example 2:
(1) 1g of lithium fluoride (LiF) was dissolved in a dilute hydrochloric acid (HCl) solution and stirred thoroughly, after which Ti was dissolved 3 AlC 2 Slowly adding the powder into the above solution, reacting at 35deg.C in water bath for 24 hr, centrifuging at 5000rpm for 5min, washing the precipitate with waterpH of layer liquid>6. The precipitate was collected and added to 100mLH 2 O, deoxidizing under argon for 15min, and then carrying out ultrasonic treatment for 1h. Finally, the precipitate is removed by centrifugation again, and the collected liquid is freeze-dried to obtain the etched MXene nano-sheet. And (3) introducing argon to protect the freeze-dried MXene nano-sheet powder for later use.
(2) 20mg of MXene was dissolved in water and subjected to ultrasonic dispersion, and Tris-HCl buffer (1M) was added to adjust the pH of the solution to about 8.5. To the above solution, a certain amount of dopamine hydrochloride (DA) was added, and reacted for 1 hour under an air atmosphere. The reaction solution was then centrifuged at 8900rpm for 10min, and the precipitate was washed with water 3 times to remove unreacted DA. Finally, the precipitate was collected by centrifugation and freeze-dried to give the final product mxene@pda. And (5) introducing argon into the freeze-dried MXene@PDA powder for storage for later use.
(3) 1.5g Chitosan (CS) was dissolved in deionized water with pH adjusted to about 5 with 5M HCl to form a 1wt% chitosan solution. Heating the solution to 50deg.C in a water bath, and using N 2 Deoxygenation is performed for 15min, and then 0.8g of Gallic Acid (GA) is added to the chitosan solution. 575.1mg of N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (EDC) and 345.3mg of N-hydroxysuccinimide (NHS) were dissolved in a mixture of 50mL of ethanol and water (1:1, v/v), and added dropwise to the above mixed solution, in N 2 The reaction was carried out for 10 hours under ambient conditions and the pH was kept at 5. The resulting solution was dialyzed in acidified deionized water containing NaCl for 3 days using a dialysis bag. Finally, the obtained solution was freeze-dried to obtain gallic acid-modified chitosan powder (CS-GA).
(4) 1g of Hyaluronic Acid (HA) was dissolved in 100mL of deionized water, and after stirring well, 1g of sodium periodate (NaIO) was added thereto 4 ) The reaction was carried out for 3h under dark conditions. Then, 3mL of ethylene glycol was added to the above solution to terminate the reaction, and stirring was continued for 1h. The resulting solution was dialyzed in deionized water using a dialysis bag for three days, and finally the resulting solution was freeze-dried to obtain the aldehyde-formed hyaluronic acid (HA-ALD).
(5) A solution containing 5wt% of HA-ALD and Mxene@PDA (0 mg/mL) was prepared with water as a solvent and mixed well by sonication. Then, the above solution was mixed with 3wt% CS-GA aqueous solution in a volume ratio of 1:1, shaking and mixing. The injectable hydrogel is obtained after uniform mixing. The hydrogel containing no Mxene@PDA, namely hydrogel GH for short, has a certain antibacterial effect in a moderate number of bacterial colonies in an antibacterial experiment, and obtains a general diabetic wound repairing result.
Example 3:
(1) 1g of lithium fluoride (LiF) was dissolved in a dilute hydrochloric acid (HCl) solution and stirred thoroughly, after which Ti was dissolved 3 AlC 2 Slowly adding the powder into the above solution, reacting at 35deg.C in water bath for 24 hr, centrifuging at 5000rpm for 5min, washing the precipitate with water to pH of the supernatant liquid>6. The precipitate was collected and added to 100mLH 2 O, deoxidizing under argon for 15min, and then carrying out ultrasonic treatment for 1h. Finally, the precipitate is removed by centrifugation again, and the collected liquid is freeze-dried to obtain the etched MXene nano-sheet. And (3) introducing argon to protect the freeze-dried MXene nano-sheet powder for later use.
(2) 20mg of MXene was dissolved in water and subjected to ultrasonic dispersion, and Tris-HCl buffer (1M) was added to adjust the pH of the solution to about 8.5. To the above solution, a certain amount of dopamine hydrochloride (DA) was added, and reacted for 1 hour under an air atmosphere. The reaction solution was then centrifuged at 8900rpm for 10min, and the precipitate was washed with water 3 times to remove unreacted DA. Finally, the precipitate was collected by centrifugation and freeze-dried to give the final product mxene@pda. And (5) introducing argon into the freeze-dried MXene@PDA powder for storage for later use.
(3) 1.5g Chitosan (CS) was dissolved in deionized water with pH adjusted to about 5 with 5M HCl to form a 1wt% chitosan solution. Heating the solution to 50deg.C in a water bath, and using N 2 Deoxygenation is performed for 15min, and then 0g of Gallic Acid (GA) is added to the chitosan solution. 575.1mg of N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (EDC) and 345.3mg of N-hydroxysuccinimide (NHS) were dissolved in a mixture of 50mL of ethanol and water (1:1, v/v), and added dropwise to the above mixed solution, in N 2 The reaction was carried out for 10 hours under ambient conditions and the pH was kept at 5. The resulting solution was dialyzed in acidified deionized water containing NaCl for 3 days using a dialysis bag. Finally, the obtained solution was freeze-dried to obtain gallic acid-modified chitosan powder (CS-GA).
(4) 1g of Hyaluronic Acid (HA) was dissolved in 100mL of deionized water, and after stirring well, 1g of sodium periodate (NaIO) was added thereto 4 ) The reaction was carried out for 3h under dark conditions. Then, 3mL of ethylene glycol was added to the above solution to terminate the reaction, and stirring was continued for 1h. The resulting solution was dialyzed in deionized water using a dialysis bag for three days, and finally the resulting solution was freeze-dried to obtain the aldehyde-formed hyaluronic acid (HA-ALD).
(5) A solution containing 5wt% of HA-ALD and Mxene@PDA (0 mg/mL) was prepared with water as a solvent and mixed well by sonication. Then, the above solution was mixed with 3wt% CS-GA aqueous solution in a volume ratio of 1:1, shaking and mixing. The injectable hydrogel is obtained after uniform mixing. The hydrogel containing neither gallic acid GA nor Mxene@PDA, abbreviated as hydrogel CH, has the greatest colony number in an antibacterial experiment, shows that the antibacterial effect is relatively worst, and obtains a slower diabetic wound repairing result.
Claims (4)
1. A preparation method of injectable conductive hydrogel with antioxidant stress characteristics is characterized in that: the steps and conditions are as follows:
(1) 1g of lithium fluoride (LiF) was dissolved in a dilute hydrochloric acid (HCl) solution and stirred thoroughly, after which Ti was dissolved 3 AlC 2 Slowly adding the powder into the above solution, reacting at 35deg.C in water bath for 24 hr, centrifuging at 5000rpm for 5min, washing the precipitate with water to pH of the supernatant liquid>6, preparing a base material; the precipitate was collected and added to 100mLH 2 O, deoxidizing under argon for 15min, and then carrying out ultrasonic treatment for 1h; finally, centrifuging again to remove sediment, and freeze-drying the collected liquid to obtain etched MXene nano-sheets; introducing argon into the freeze-dried MXene nano-sheet powder for protection and standby;
(2) Dissolving 20mg of MXene in water for ultrasonic dispersion, and adding Tris-HCl buffer solution (1M) to adjust the pH of the solution to about 8.5; adding a certain amount of dopamine hydrochloride (DA) into the solution, and reacting for 1h in an air environment; the reaction solution was then centrifuged at 8900rpm for 10min, and the precipitate was washed with water 3 times to remove unreacted DA; finally, centrifugally collecting the precipitate, and freeze-drying the precipitate to obtain a final product Mxene@PDA; introducing argon into the freeze-dried MXene@PDA powder for later use;
(3) 1.5g of Chitosan (CS) was dissolved in deionized water with pH adjusted to about 5 with 5M HCl to form a 1wt% chitosan solution; heating the solution to 50deg.C in a water bath, and using N 2 Deoxidizing for 15min, and then adding 0-1.5 g of Gallic Acid (GA) into the chitosan solution; 575.1mg of N- (3-dimethylaminopropyl) -N' -ethylcarbodiimide hydrochloride (EDC) and 345.3mg of N-hydroxysuccinimide (NHS) were dissolved in a mixture of 50mL of ethanol and water (1:1, v/v), and added dropwise to the above mixed solution, in N 2 Reacting for 10 hours in the environment, and keeping the pH at 5; dialyzing the obtained solution in acidified deionized water containing NaCl for 3 days by using a dialysis bag; finally, freeze-drying the obtained solution to obtain gallic acid modified chitosan powder (CS-GA);
(4) 1g of Hyaluronic Acid (HA) was dissolved in 100mL of deionized water, and after stirring well, 1g of sodium periodate (NaIO) was added thereto 4 ) Reacting for 3 hours under the light-shielding condition; then, adding 3mL of ethylene glycol into the solution to terminate the reaction, and continuously stirring for 1h; dialyzing the obtained solution in deionized water for three days by using a dialysis bag, and finally freeze-drying the obtained solution to obtain aldehyde hyaluronic acid (HA-ALD);
(5) Preparing a solution containing 5wt% of HA-ALD and Mxene@PDA (0-5 mg/mL) by using water as a solvent, and uniformly mixing by ultrasonic; then, the above solution was mixed with 3wt% CS-GA aqueous solution in a volume ratio of 1:1, oscillating and mixing; the injectable hydrogel is obtained after uniform mixing.
2. An injectable conductive hydrogel having antioxidant stress characteristics prepared by the method of claim 1, wherein: due to the interaction of natural or synthetic polymers such as chitosan, gallic acid, polydopamine and the like, the hydrogel has excellent broad-spectrum antibacterial property, and has the characteristics of injectability, strong adhesiveness, mechanical strength and the like; as wound dressing, the wound dressing is used for filling deep wound surface with irregular shape.
3. An injectable conductive hydrogel having antioxidant stress characteristics prepared by the method of claim 1, wherein: the hydrogel is of a loose porous structure, so that wound seepage can be absorbed conveniently; the hydrogel has the characteristics of good conductivity, acceleration of wound repair by promoting information communication among epidermal cells, and the like.
4. An injectable conductive hydrogel having antioxidant stress characteristics prepared by the method of claim 1, wherein: the hydrogel is used as a dressing, and due to the synergistic effect of the multiple components of the gallic acid, the Mxene nano-sheet and the polydopamine, free radicals are effectively removed, oxidation of DNA, protein and lipid in cells is inhibited, the strong antioxidation stress characteristic is obtained, the repair of diabetic foot infection type chronic wound surface is remarkably accelerated, and the hydrogel is applied as a dressing of the infection type chronic wound surface and a tissue regeneration auxiliary material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310765188.8A CN116603098A (en) | 2023-06-27 | 2023-06-27 | Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310765188.8A CN116603098A (en) | 2023-06-27 | 2023-06-27 | Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116603098A true CN116603098A (en) | 2023-08-18 |
Family
ID=87678412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310765188.8A Pending CN116603098A (en) | 2023-06-27 | 2023-06-27 | Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116603098A (en) |
-
2023
- 2023-06-27 CN CN202310765188.8A patent/CN116603098A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | Self-healing polysaccharide-based injectable hydrogels with antibacterial activity for wound healing | |
| Huang et al. | Biodegradable gelatin/silver nanoparticle composite cryogel with excellent antibacterial and antibiofilm activity and hemostasis for Pseudomonas aeruginosa-infected burn wound healing | |
| Ou et al. | Advances in multifunctional chitosan-based self-healing hydrogels for biomedical applications | |
| CN110117369B (en) | Antibacterial adhesive conductive hydrogel and preparation method and application thereof | |
| Yao et al. | Design strategies for adhesive hydrogels with natural antibacterial agents as wound dressings: Status and trends | |
| CN110448722A (en) | A kind of injectable is containing the temperature sensitive composite antibacterial hydrogel material of tannic acid and its preparation and application | |
| Han et al. | A multifunctional mussel-inspired hydrogel with antioxidant, electrical conductivity and photothermal activity loaded with mupirocin for burn healing | |
| CN112480434B (en) | Copper ion antibacterial hydrogel and preparation method and application thereof | |
| Zhao et al. | Electroactive injectable hydrogel based on oxidized sodium alginate and carboxymethyl chitosan for wound healing | |
| JP5907489B2 (en) | Hydrogels derived from chitosan derivatives | |
| Ehtesabi et al. | Carbon dot-based materials for wound healing applications | |
| CN116650710A (en) | Mussel inspired multifunctional double-network crosslinked hydrogel wound dressing | |
| CN115926200A (en) | Preparation method and application of enzyme-catalyzed double-crosslinked polymer composite hydrogel material | |
| CN109745579B (en) | Injectable self-healing hydrogel with electrical conductivity and preparation method thereof | |
| Li et al. | Rapid in situ deposition of iron-chelated polydopamine coating on the polyacrylamide hydrogel dressings for combined photothermal and chemodynamic therapy of skin wound infection | |
| Liang et al. | Natural hydrogel dressings in wound care: Design, advances, and perspectives | |
| CN115382008B (en) | Preparation method of injectable hydrogel suitable for diabetic wound repair | |
| CN115850733B (en) | Nanoclay hydrogel for injection and preparation method and application thereof | |
| CN116603098A (en) | Injectable conductive hydrogel with antioxidant stress characteristic and preparation method and application thereof | |
| CN108421042B (en) | Preparation method of light-operated degradable hydrogel | |
| CN116440317A (en) | Photothermal antibacterial hydrogel and preparation method thereof | |
| CN113214508B (en) | Natural antibacterial gel for skin repair and preparation method thereof | |
| CN111840634B (en) | Preparation method and application of grape seed extract hydrogel | |
| CN114539558A (en) | Hydrogel material with inherent antibacterial, antioxidant and adhesion properties and preparation method and application thereof | |
| Wang et al. | Multifunctional hydrogels for chronic wounds repairing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |